< Back to previous page


Low frequency of liver enzyme elevation in HIV-infected patients attending a large urban treatment centre in Uganda

Journal Contribution - Journal Article

Liver enzyme elevations among patients on antiretroviral therapy (ART) were determined by prospectively evaluating aspartate aminotransferase (AST) data in a cohort of patients in Kampala over 36 months. A proportion of patients had hepatitis B virus (HBV) status determined. Hepatotoxicity was graded I to IV according to the AIDS Clinical Trial Group criteria. Of 546 patients, 377 (69%) were women; overall median baseline CD4+ T-cell was 97/muL (interquartile range [IQR] 20-164). Hepatitis B surface antigen (HBsAg) was detected in 42 (9%) of 470 persons. ART included lamivudine, with either nevirapine and d4T (74%) or efavirenz and AZT (26%). Median (IQR) AST level at baseline was 35 (27, 53 IU/L). Over 36 months, only eight patients had grade III AST elevation. Neither HBsAg nor ART regimen influenced AST levels. Male gender and CD4+ change from baseline were correlated with AST elevation. Patients with HIV/HBV co-infection were not at an increased risk of AST elevation, which occurred uncommonly in this setting
Journal: International Journal of STD & AIDS
ISSN: 0956-4624
Issue: 8
Volume: 21
Pages: 553-557
Publication year:2010
Keywords:Viral diseases, HIV, AIDS, HAART, Antiretrovirals, Liver, Enzymes, Toxicity, Liver stage, Hepatitis B, Antigens, Lamivudine, Nevirapine, Efavirenz, AZT, Gender, CD4+, Uganda, Africa-East
  • Scopus Id: 78049450483
  • PubMed Id: 20975087